16.57
0.12%
-0.02
After Hours:
16.50
-0.07
-0.42%
Overview
News
Price History
Option Chain
Financials
Why TEVA Down?
Discussions
Forecast
Stock Split
Dividend History
Teva Pharmaceutical Industries Ltd Adr stock is traded at $16.57, with a volume of 9.20M.
It is down -0.12% in the last 24 hours and down -7.43% over the past month.
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
See More
Previous Close:
$16.59
Open:
$16.54
24h Volume:
9.20M
Relative Volume:
1.44
Market Cap:
$18.77B
Revenue:
$16.77B
Net Income/Loss:
$-959.00M
P/E Ratio:
-8.285
EPS:
-2
Net Cash Flow:
$1.37B
1W Performance:
-2.70%
1M Performance:
-7.43%
6M Performance:
-0.18%
1Y Performance:
+67.71%
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Name
Teva Pharmaceutical Industries Ltd Adr
Sector
Phone
972 (3) 914-8213
Address
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-10-24 | Upgrade | Argus | Hold → Buy |
Mar-08-24 | Upgrade | JP Morgan | Underweight → Neutral |
Feb-12-24 | Upgrade | Piper Sandler | Neutral → Overweight |
Jan-23-24 | Upgrade | Jefferies | Hold → Buy |
Jan-03-24 | Upgrade | Piper Sandler | Underweight → Neutral |
Dec-18-23 | Initiated | HSBC Securities | Buy |
Nov-27-23 | Upgrade | UBS | Neutral → Buy |
Jul-06-23 | Upgrade | UBS | Sell → Neutral |
May-25-23 | Initiated | Morgan Stanley | Equal-Weight |
May-18-23 | Upgrade | Evercore ISI | In-line → Outperform |
Jan-19-23 | Downgrade | Jefferies | Buy → Hold |
Nov-14-22 | Downgrade | JP Morgan | Neutral → Underweight |
Nov-04-22 | Downgrade | UBS | Neutral → Sell |
Oct-21-22 | Resumed | Jefferies | Buy |
Aug-05-22 | Upgrade | BofA Securities | Neutral → Buy |
Jun-14-22 | Resumed | UBS | Neutral |
May-17-22 | Upgrade | BofA Securities | Underperform → Neutral |
May-04-22 | Downgrade | Piper Sandler | Neutral → Underweight |
Apr-05-22 | Upgrade | Barclays | Equal Weight → Overweight |
Mar-25-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
Jan-27-22 | Downgrade | Argus | Buy → Hold |
Oct-28-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
May-04-21 | Downgrade | UBS | Buy → Neutral |
Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
Nov-25-20 | Initiated | Oppenheimer | Perform |
Aug-06-20 | Upgrade | Barclays | Underweight → Equal Weight |
Jul-27-20 | Resumed | Goldman | Neutral |
Jun-01-20 | Upgrade | SunTrust | Hold → Buy |
Apr-24-20 | Resumed | Citigroup | Neutral |
Apr-06-20 | Upgrade | UBS | Neutral → Buy |
Feb-24-20 | Downgrade | Edward Jones | Hold → Sell |
Nov-12-19 | Upgrade | JP Morgan | Underweight → Neutral |
Oct-17-19 | Upgrade | Gabelli & Co | Hold → Buy |
Aug-07-19 | Downgrade | Evercore ISI | Outperform → In-line |
Jul-19-19 | Initiated | Wolfe Research | Peer Perform |
Jul-15-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jul-10-19 | Resumed | Credit Suisse | Neutral |
Jul-05-19 | Upgrade | Argus | Hold → Buy |
Jun-11-19 | Initiated | Barclays | Underweight |
Jun-03-19 | Upgrade | Oppenheimer | Perform → Outperform |
May-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
May-28-19 | Downgrade | UBS | Buy → Neutral |
Mar-20-19 | Initiated | SunTrust | Hold |
Mar-07-19 | Resumed | UBS | Buy |
View All
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Latest News
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference - GlobeNewswire Inc.
Such Is The Power Of CNH Industrial NV (NYSE: CNH) - Stocks Register
Weekly Upgrades and Downgrades - InvestorPlace
Earnings call: Teva Pharmaceuticals sees growth amid challenges in Q3 2024 - Investing.com
Where Do Analysts See Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Heading? - Stocks Register
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
South Africa Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research
Spain Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Vontobel Holding Ltd. Sells 332,717 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) - MarketBeat
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Is Currently 5.28 below its 200 Period Moving Avg: What Does This Mean? – The DBT News - The DBT News
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
Monitoring Teva- Pharmaceutical Industries Ltd. ADR (TEVA) after recent insider movements - Knox Daily
Views of Wall Street’s Leading Experts on Teva- Pharmaceutical Industries Ltd. ADR - SETE News
Selling Buzz: Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Exec. VP, European Commercial Daniell Richard sells 98,943 shares of the company – Knox Daily - Knox Daily
Qifu Technology Inc. ADR (QFIN) gets rating Initiated from Nomura - Knox Daily
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Is Currently 1.45 below its 200 Period Moving Avg: What Does This Mean? – The DBT News - The DBT News
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
Keeping an Eye on Teva- Pharmaceutical Industries Ltd. ADR (TEVA) After Insider Trading Activity - Knox Daily
TEVA’s current quarter earnings: What analysts forecast? - US Post News
Taking a look at what insiders are doing to gauge the Teva- Pharmaceutical Industries Ltd. ADR (TEVA)’s direction - Knox Daily
HP Stock Sees Surge of Approximately 3.50% in Last Five Days - Knox Daily
RPM International, Inc. [RPM] Shares Rise 6.30 % on Wednesday - Knox Daily
Alight Inc. (ALIT) gets rating Downgrade from JP Morgan - Knox Daily
TEVA’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Keycorp (NYSE: KEY) Up 50.91% This Year: What Is Going To Happen Next - Stocks Register
Argus upgrades Teva- Pharmaceutical Industries Ltd. ADR (TEVA) rating to a Buy - Knox Daily
TE Connectivity Ltd’s latest rating changes from various analysts - Knox Daily
FTCI’s latest rating updates from top analysts. - Knox Daily
Teva- Pharmaceutical Industries Ltd. ADR (TEVA): Worth A Small Bite At $17.54 - Stocks Register
How will Teva- Pharmaceutical Industries Ltd. ADR’s (TEVA) earnings compare to estimates this quarter? - US Post News
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Shares Jump Approximately 70.34% Over the Year - Knox Daily
Before You Invest, Make Sure You Check This New Oriental Education & Technology Group Inc. ADR (NYSE: EDU) Analysis – Stocks Register - Stocks Register
TEVA’s Market Flip-Flop: Exploring the Volatility of 2023 Performance - The InvestChronicle
Does Walmart Inc (NYSE: WMT) Still Need To Convince Analysts? - Stocks Register
When Would Be The Best Time To Buy UiPath Inc (NYSE: PATH) Stock? - Stocks Register
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Stock trading around $17.72 per share: What’s Next? - The DBT News
Checking in on Teva- Pharmaceutical Industries Ltd. ADR (TEVA) after recent insiders movement - Knox Daily
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY (risperidone) Extended-Release Injectable Suspension from Perseris (RBP-7000) - wallstreet:online
DLTR Shares Experience Surge in Value - Knox Daily
A company insider recently sold 708 shares of NAPCO Security Technologies Inc [NSSC]. Should You Sale? - Knox Daily
TEVA Shares Experience Surge in Value - Knox Daily
Does Teva- Pharmaceutical Industries Ltd. ADR (TEVA) offer a good opportunity for investors? - SETE News
How analysts predict Teva- Pharmaceutical Industries Ltd. ADR (TEVA) will perform this quarter? - US Post News
Argus analysts upgrades a Buy rating for Teva- Pharmaceutical Industries Ltd. ADR (TEVA) - Knox Daily
Teva- Pharmaceutical Industries Ltd. ADR Inc. (TEVA) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
What will the future hold for Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) stock? - US Post News
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):